Status:
UNKNOWN
The Effect of 0.5% Roxithromycin Lotion for Androgenetic Alopecia
Lead Sponsor:
Hamamatsu University
Conditions:
Alopecia
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
The purpose of this study is exploiting the new drugs for androgenetic alopecia because there are still no effective and safe topical drug for androgenetic alopecia. Roxithomycin is one of the macroli...
Detailed Description
The topical therapy for androgenetic alopecia is still not enough to improve cosmetically. Thereforem we try to find new effective and safe topical therapy for this disease. Roxithromycin has not only...
Eligibility Criteria
Inclusion
- Androgenetic alopecia
Exclusion
- Cicatricial alopecia
- Allergy to roxitromycin
- Children (19years old or younger)
- Pregnant female
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00197379
Start Date
May 1 2005
End Date
January 1 2007
Last Update
July 29 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Dermatology, Hamamatsu University School of Medicine
Hamamatsu, Japan, 431-3192